Description
RAS癌蛋白是癌症发生和进展的关键驱动因素，在近20%的癌症病例中存在激活突变，其中KRAS是最常见的。虽然KRAS抑制剂在非小细胞肺癌（NSCLC）、结直肠癌（CRC）和胰腺导管腺癌（PDAC）等多种癌症类型中显示出早期疗效，但单药治疗的临床效果因原发性和获得性耐药而受限。本简报详细审查了RAS抑制在癌症治疗中的临床前和临床数据，描述了多种遗传和非遗传耐药机制，并强调了未来通过合理组合疗法克服耐药和增强治疗效果的机会。References: Ebright R Y, Dilly J, Shaw A T, et al. Response and Resistance to RAS Inhibition in Cancer[J]. Cancer Discovery, 2025: OF1-OF25.
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Trump $82 Million Bond Spree, Brazil Tariffs 'Too High,' More
16 Nov 2025
Bloomberg News Now
Ex-Fed Gov Resigned After Rules Violations, Trump Buys $82 Mil of Bonds, More
16 Nov 2025
Bloomberg News Now
THIS TRUMP INTERVIEW WAS INSANE!
16 Nov 2025
HasanAbi
Epstein Emails and Trump's Alleged Involvement
15 Nov 2025
Conspiracy Theories Exploring The Unseen
New Epstein Emails Directly Implicate Trump - H3 Show #211
15 Nov 2025
H3 Podcast
Trump Humiliates Himself on FOX as They Call Him Out
15 Nov 2025
IHIP News